The cholesterol numbers that actually predict risk.

The result comes back and the number sits comfortably in range. LDL cholesterol: normal. The patient exhales. Their clinician, reading the same sheet, is not quite ready to. Because the line everyone fixes on measures the cargo inside the particles, and says almost nothing about how many particles there are — and it is the particle count, not the cargo, that keeps turning up in the risk data.

Cholesterol has been the headline of the heart-health story for so long that most of us think we know the plot. Keep LDL down, keep HDL up, and you’ve done your bit. It’s a reasonable summary of a much stranger picture. The standard lipid panel is a useful, cheap, decades-old tool. It also leaves two of the most informative numbers off the page.

What a standard panel actually measures

When your results list LDL-C, that’s LDL cholesterol: an estimate of how much cholesterol is riding inside your low-density lipoprotein particles. Think of a fleet of delivery trucks. LDL-C tells you roughly how much cargo the fleet is carrying. What it doesn’t tell you is how many trucks are on the road.

That distinction sounds academic until you learn what actually happens in an artery wall. It isn’t loose cholesterol that lodges there and begins the slow work of a plaque. It’s the particles — each one small enough to slip into the wall and get stuck. More particles on the road means more chances for one to lodge. And two people can carry the identical amount of cargo across a very different number of trucks.

ApoB: counting the particles, not the cargo

Here’s the elegant part. Nearly every particle capable of driving atherosclerosis — LDL, and a few of its relatives — carries exactly one copy of a protein called apolipoprotein B, or ApoB. One particle, one ApoB. So a single blood measurement of ApoB is, in effect, a direct headcount of the trucks.

That’s why ApoB is associated with cardiovascular risk more tightly than LDL-C in a good deal of the research: it counts the thing that does the damage instead of estimating what’s inside it. When the two numbers agree, either will do. When they disagree — a normal LDL-C sitting on top of a high particle count — ApoB is the one that has been telling the truer story.

Lp(a): the inherited number you measure once

The second number is stranger, and more personal. Lipoprotein(a) — said “LP-little-a,” written Lp(a) — is an LDL-like particle with an extra protein wrapped around it. Your level is set almost entirely by the genes you were born with. It barely moves with diet, exercise, or the usual medications. It is, for most people, a number you are simply dealt.

Roughly one in five people carries an elevated level, and the vast majority have no idea, because a standard panel doesn’t look for it. Where it’s elevated, it’s associated with a higher lifetime cardiovascular risk that runs quietly in the background of everything else. Because it’s genetic and stable, the usual approach is refreshingly simple: measure it once, know your number, and factor it in for good.

Knowing you carry a high Lp(a) doesn’t mean something is wrong today. It means one of your inherited cards is now face-up instead of hidden — and that’s a strictly better place to plan from. What to do about it is a conversation for you and a clinician, not a verdict a web page can hand down.

Why a “normal” panel can still miss it

Put the two together and you can see the blind spot. A reassuring LDL-C can sit alongside a high ApoB, or a perfectly ordinary panel can hide an elevated Lp(a) that was never measured. Clinicians call the first mismatch discordance, and it’s common enough that measuring only LDL-C leaves real information on the table.

None of this makes the standard panel wrong. It makes it incomplete — a first look rather than the last word.

How they’re measured

The good news is that none of this needs new technology. Both numbers come from an ordinary blood draw; they simply have to be ordered. There’s a natural progression.

You don’t need a specialist to start — these are standard tests a clinician can order. What matters is having someone read them together, in the context of the rest of your health.

How they’re managed

There’s no trick here either, and the honest version is less exciting than the internet’s. What the evidence keeps returning to is a familiar, durable set of levers — the same ones that quietly move most of cardiometabolic health:

• The fundamentals, first. A way of eating you can sustain, regular movement, not smoking, and decent sleep are associated with a healthier particle picture for many people. They’re the foundation everything else is built on.
• ApoB is the number to re-check. Because it responds, it’s worth tracking. Change one or two things, then measure again and see whether the count actually moved.
• Lp(a) is played differently. Since it barely responds to lifestyle, an elevated Lp(a) usually shifts the strategy toward managing everything else — the modifiable risks — more tightly, so the one fixed card matters less.
• Medical options, where a clinician says so. For some people, after a proper evaluation, treatment enters the conversation. That’s a decision made with a care team, never a checkout button — and this page is not that conversation.

The Peak You approach

That loop is the whole idea behind Peak You: measure → understand → manage → re-test. Your numbers arrive in plain language rather than a wall of reference ranges, read in the context of the rest of your health, and — where it’s warranted — turned into a clinician-guided plan aimed at the fundamentals, with a re-test to show whether anything moved. A single reading is a snapshot. What matters is where the next one lands.

Frequently asked